MedTrace Logo

NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma

NCT03353896 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-12-10

No results posted yet for this study

Summary

This pilot clinical trial studies the side effects of NovoTTF-200A device in treating patients with newly diagnosed high risk oligodendroglioma. NovoTTF-200A device is a portable battery operated device which produces tumor treating (TT)Fields in the body by means of surface electrodes placed on the skin. TTFields are very low intensity, intermediate frequency electric fields that may slow the growth of tumor cells in patients with high risk oligodendroglioma.

Conditions

  • Anaplastic Oligodendroglioma
  • Oligoastrocytoma
  • Oligodendroglioma

Interventions

DEVICE

Wear novoTTF-200A

Wear novoTTF-200A device

PROCEDURE

Quality-of-Life Assessment

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • NovoCure Ltd.

    collaborator INDUSTRY

  • University of Southern California

    lead OTHER

Principal Investigators

  • Thomas Chen, MD · University of Southern California

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2020-12-08
Completion
2020-12-08
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03353896 on ClinicalTrials.gov